NYSE:MRX - Medicis Pharmaceutical Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Medicis Pharmaceutical logoMedicis Pharmaceutical Corporation (Medicis) together with its wholly owned subsidiaries is an independent specialty pharmaceutical company engaged in the development and marketing of products for the treatment of dermatological and aesthetic conditions in the United States and Canada. Medicis offers a range of products addressing various conditions or aesthetic improvements, including facial wrinkles. Its brands are DYSPORT (abobotulinumtoxinA) 300 Units for Injection, PERLANE Injectable Gel, RESTYLANE Injectable Gel, SOLODYN (minocycline HCl, USP) Extended Release Tablets, VANOS (fluocinonide) Cream 0.1%, ZIANA (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel and ZYCLARA (imiquimod) Cream 3.75% and 2.5%. As of December 31, 2011, it offered 27 branded products. On December 2, 2011, it acquired Graceway Pharmaceuticals, LLC (Graceway). On November 1, 2011, Medicis sold Medicis Technologies Corporation, formerly LipoSonix, Inc., to Solta Medical, Inc. (Solta).

Receive MRX News and Ratings via Email

Sign-up to receive the latest news and ratings for MRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNYSE:MRX
CUSIPN/A
Phone+1-212-5992000

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A
Market Cap$0.00

Medicis Pharmaceutical (NYSE:MRX) Frequently Asked Questions

What is Medicis Pharmaceutical's stock symbol?

Medicis Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRX."

Who are Medicis Pharmaceutical's key executives?

Medicis Pharmaceutical's management team includes the folowing people:
  • Robert Roswell Chai-Onn, Executive Vice President, General Counsel, Secretary, Director (Age 44)
  • Howard Bradley Schiller, Officer, Director (Age 53)
  • Ryan Weldon, Officer, Director

Has Medicis Pharmaceutical been receiving favorable news coverage?

Media coverage about MRX stock has been trending somewhat positive on Thursday, Accern reports. Accern rates the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Medicis Pharmaceutical earned a news impact score of 0.18 on Accern's scale. They also assigned news stories about the healthcare company an impact score of 46.57 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days. View Recent Headlines for Medicis Pharmaceutical.

How do I buy shares of Medicis Pharmaceutical?

Shares of MRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Medicis Pharmaceutical?

Medicis Pharmaceutical's mailing address is 8125 N Hayden Rd, SCOTTSDALE, AZ 85258-2463, United States. The healthcare company can be reached via phone at +1-212-5992000.


MarketBeat Community Rating for Medicis Pharmaceutical (NYSE MRX)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  120 (Vote Outperform)
Underperform Votes:  133 (Vote Underperform)
Total Votes:  253
MarketBeat's community ratings are surveys of what our community members think about Medicis Pharmaceutical and other stocks. Vote "Outperform" if you believe MRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel